Limits...
Effects of Combined Soy Isoflavone Extract and Docetaxel Treatment on Murine 4T1 Breast Tumor Model.

Hejazi E, Nasrollahzadeh J, Fatemi R, Barzegar-Yar Mohamadi L, Saliminejad K, Amiri Z, Kimiagar M, Houshyari M, Tavakoli M, Idali F - Avicenna J Med Biotechnol (2015 Jan-Mar)

Bottom Line: In DOCE+SIE group, diet consumption was significantly higher than DOCE group.The mRNA expression was not significantly different among groups.The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Background: Emergence of drug resistance has brought major problems in chemotherapy. Using nutrients in combination with chemotherapy could be beneficial for improvement of sensitivity of tumors to drug resistance. Soybean-derived isoflavones have been suggested as chemopreventive agents for certain types of cancer, particularly breast cancer. In this study, the synergistic effects of soy isoflavone extract in combination with docetaxel in murine 4T1 breast tumor model were investigated.

Methods: In this study, mice were divided into 4 groups (15 mice per group) of control, the dietary Soy Isoflavone Extract (SIE, 100 mg/kg diet), the Docetaxel (DOCE, 10 mg/kg) injection and the combination of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE). After 3 injections of docetaxel (once a week), 7 mice were sacrificed to analyze MKI67 gene and protein expressions and the rest were monitored for diet consumption, tumor growth and survival rates.

Results: In DOCE+SIE group, diet consumption was significantly higher than DOCE group. While lifespan showed a trend towards improvement in DOCE+SIE group, no significant difference was observed among the 4 studied groups. Tumor volume was not significantly affected in treated groups. A lower but not significant MKI67 protein expression was detected in western blot in DOCE+SIE group. The mRNA expression was not significantly different among groups.

Conclusion: The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

No MeSH data available.


Related in: MedlinePlus

MKI67 mRNA and protein expressions in different groups. The control, the dietary Soy Isoflavones Extract (SIE), the intravenous docetaxel injection (DOCE) and the combination group of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE) groups are shown. A) Relative expression of MKI67 gene in different groups; B) Western blot analysis of MKI67; C) β-actin. No significant differences between groups were detected.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4388885&req=5

Figure 0004: MKI67 mRNA and protein expressions in different groups. The control, the dietary Soy Isoflavones Extract (SIE), the intravenous docetaxel injection (DOCE) and the combination group of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE) groups are shown. A) Relative expression of MKI67 gene in different groups; B) Western blot analysis of MKI67; C) β-actin. No significant differences between groups were detected.

Mentions: No significant differences in MKi67gene expressions were observed among the groups. However, it seems that SIE may induce MKI67 mRNA expression and thereby cell proliferation (Figure 4). In western blot analysis two bands of 345 and 395 kDa, related to MKI67 protein were detected. The lowest expression of MKI67 protein was seen in DOCE+SIE group and an increase in its expression in DOCE was observed in SIE and the control groups, respectively.


Effects of Combined Soy Isoflavone Extract and Docetaxel Treatment on Murine 4T1 Breast Tumor Model.

Hejazi E, Nasrollahzadeh J, Fatemi R, Barzegar-Yar Mohamadi L, Saliminejad K, Amiri Z, Kimiagar M, Houshyari M, Tavakoli M, Idali F - Avicenna J Med Biotechnol (2015 Jan-Mar)

MKI67 mRNA and protein expressions in different groups. The control, the dietary Soy Isoflavones Extract (SIE), the intravenous docetaxel injection (DOCE) and the combination group of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE) groups are shown. A) Relative expression of MKI67 gene in different groups; B) Western blot analysis of MKI67; C) β-actin. No significant differences between groups were detected.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4388885&req=5

Figure 0004: MKI67 mRNA and protein expressions in different groups. The control, the dietary Soy Isoflavones Extract (SIE), the intravenous docetaxel injection (DOCE) and the combination group of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE) groups are shown. A) Relative expression of MKI67 gene in different groups; B) Western blot analysis of MKI67; C) β-actin. No significant differences between groups were detected.
Mentions: No significant differences in MKi67gene expressions were observed among the groups. However, it seems that SIE may induce MKI67 mRNA expression and thereby cell proliferation (Figure 4). In western blot analysis two bands of 345 and 395 kDa, related to MKI67 protein were detected. The lowest expression of MKI67 protein was seen in DOCE+SIE group and an increase in its expression in DOCE was observed in SIE and the control groups, respectively.

Bottom Line: In DOCE+SIE group, diet consumption was significantly higher than DOCE group.The mRNA expression was not significantly different among groups.The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Background: Emergence of drug resistance has brought major problems in chemotherapy. Using nutrients in combination with chemotherapy could be beneficial for improvement of sensitivity of tumors to drug resistance. Soybean-derived isoflavones have been suggested as chemopreventive agents for certain types of cancer, particularly breast cancer. In this study, the synergistic effects of soy isoflavone extract in combination with docetaxel in murine 4T1 breast tumor model were investigated.

Methods: In this study, mice were divided into 4 groups (15 mice per group) of control, the dietary Soy Isoflavone Extract (SIE, 100 mg/kg diet), the Docetaxel (DOCE, 10 mg/kg) injection and the combination of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE). After 3 injections of docetaxel (once a week), 7 mice were sacrificed to analyze MKI67 gene and protein expressions and the rest were monitored for diet consumption, tumor growth and survival rates.

Results: In DOCE+SIE group, diet consumption was significantly higher than DOCE group. While lifespan showed a trend towards improvement in DOCE+SIE group, no significant difference was observed among the 4 studied groups. Tumor volume was not significantly affected in treated groups. A lower but not significant MKI67 protein expression was detected in western blot in DOCE+SIE group. The mRNA expression was not significantly different among groups.

Conclusion: The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

No MeSH data available.


Related in: MedlinePlus